Clinical Trials Browser

Sarcoma, Alveolar Soft Part

Multiple Myeloma

Lymphoma, Large B-Cell, Diffuse

Wilms Tumor, Neurofibrosarcoma, Rhabdoid Tumor

Lymphoma, Extranodal NK-T-Cell

Multiple Myeloma

Leukemia, Myeloid, Acute

Multiple Myeloma, Recurrence

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma

Multiple Myeloma

Lymphoma, Extranodal NK-T-Cell

Extensive Stage Lung Small Cell Cancer

Multiple Myeloma

Multiple Myeloma

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Multiple Myeloma

Carcinoma, Carcinoma, Pancreatic Ductal

Smoldering Multiple Myeloma, Multiple Myeloma, Neoplasms, Plasma Cell

Lymphoma, Large B-Cell, Diffuse

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

Leukemia, Myeloid, Acute

Multiple Myeloma

Lymphoma, Extranodal NK-T-Cell

Multiple Myeloma, Neoplasm, Residual

Ovarian Neoplasms, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma

Colorectal Neoplasms

Multiple Myeloma, Neoplasms, Plasma Cell

Recurrence, Leukemia, Myeloid, Acute

Multiple Myeloma, Recurrence

Leukemia, Myeloid, Acute

Multiple Myeloma

Lymphoma, B-Cell

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Leukemia, Myeloid, Acute

Richter's Transformation

Prostatic Neoplasms

Carcinoma, Carcinoma, Squamous Cell

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Multiple Myeloma

Clinical Trials

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

SELVEDge

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

SeliSarc

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

SABLe

Using Tumor Models to Determine Treatments

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

SEARCH

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT

A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

MUKtwelve

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

ClaSPd

Study of Selinexor Combined With Chidamide in Relapsed/Refractory Acute Leukemia (AML) Patients

MARCH

SAV

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

SELECT

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

KING

SIGN

SOPRA

SIRRT

SHIP

STARRS

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

STORM